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a b s t r a c t
A 62-year-old male was undergoing treatment of NHL with bone marrow involvement with
thrombocytopenia. After 15 min of starting of IV infusion of rituximab, he started having
severe retrosternal chest pain, diagnosed as acute ST elevation inferior wall MI. Patient was
pre-loadedwith dual anti platelets. Coronary angiogram showed 100% occlusion of proximal
RCA. Thrombosuction of this culprit RCA revealed underlying 90% stenosis. After that, PCI
with balloon angioplasty of RCA was done. The procedure was terminated in the view of
successful balloon angioplastywith good TIMI ﬂow. Hewas kept on dual antiplatelet therapy
for one month with regular platelet monitoring. With the growing increasing global use of
rituximab for various oncological and immunological diseases, this complication of myo-
cardial infarction should be kept inmind. Associated thrombocytopeniawith high thrombus
burden in this case heed primary coronary balloon angioplasty without stent placement a
more suitable modality.
# 2015 Cardiological Society of India. Published by Elsevier B.V. This is an open access
-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).article under the CCBY1. IntroductionAs the use of monoclonal antibodies are increasing globally in
various forms of malignancies and autoimmune diseases, we
recommend that patients with known cardiovascular risk
factors should be assessed for ischemic heart disease before
treatment and be carefully monitored during and after
treatment especially during ﬁrst infusion when tumor burden
is highest with a slow initial infusion rate, followed by
increasing the rate in 30-minute increments as tolerated.1
This life-threatening cardiovascular complication should also
be kept in mind while using rituximab in patients without
cardiovascular risk factors. Patients receiving rituximab need
to be carefully monitored during infusion and any signs andE-mail address: Ksunilverma02@gmail.com.
http://dx.doi.org/10.1016/j.ihj.2015.10.374
0019-4832/# 2015 Cardiological Society of India. Published by Elsevier
(http://creativecommons.org/licenses/by-nc-nd/4.0/).symptoms or hemodynamic derangement pertaining to
cardiovascular origin should be discussed with cardiac
physician. Any chest pain while on infusion of rituximab
warrants ECG and consultation with cardiac physician.
2. Case reportA 62-year-old male was admitted in cancer center of institute
of our hospital for treatment of NHL with bone marrow
involvement with thrombocytopenia (platelet count 64,000/
cmm). Hewas in stage IVwith no B symptoms. Histopathology
and immunohistochemistry revealed diffuse large B cell
lymphoma with CD20, CD10 positive, and Tdt negative CD3-
stained structure lymphocyteswith increased ki67. IV infusionB.V. This is an open access article under the CC BY-NC-ND license
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Fig. 1 – Electrocardiogram during chest pain ST elevation suggestive of acute inferior wall MI.
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having sudden onset of severe retrosternal chest pain with
sweating and perspiration which did not subside even after
stopping rituximab infusion and administration with sublin-
gual nitrates. Immediately, 12 lead ECG (Fig. 1) was taken
which showed ST elevation in II, III aVf, V5, and V6.
His blood pressure was 100/70 and HR was 98/min. The
echocardiography revealed hypokinesia of inferior wall of LV,
LVEF 40 to 45% without any pericardial effusion, MR, or VSR.
The patient was loaded with 325 mg of aspirin and 60 mg of
Prasugrel with the clinical prediction of primary angioplasty of
right coronary artery. Coronary angiogram showed 100%[(Fig._2)TD$FIG]
Fig. 2 – Selective right coronary angiogram showing 100%
occluded proximal right coronary artery.occlusion of proximal RCA (Fig. 2) with tight 90% stenosis in
nondominant proximal LCx with plaque in proximal LAD.
Thrombosuction revealed 90% stenosis of about 15 mm
length (Fig. 3a) which was dilated with balloons of 1.5 mm,
2.0 mm, 2.5 mm, and 3.0 mm.
The procedure was terminated here in the view of
successful POBA with about 20–30% residual stenosis
(Fig. 3b)with good TIMIﬂowwithout any underlying dissection
or residual thrombus and underlying clinical scenario. Chest
pain of patient resolved with POBA. He was discharged from
the hospital 4 days post-procedure without any complications
with platelet count of 1 lakh 7 thousand on dual ant platelet
therapy for one month with regular platelet monitoring.
3. DiscussionRituximab is a chimeric monoclonal antibody that targets the
B-cell CD20 antigen and causes rapid and speciﬁc B-cell
depletion. Biologic and chemotherapeutic agents are associ-
ated with a risk of infusion-related toxicity.2 The mechanism
by which rituximab elicits infusion reactions remains unclear,
although the symptoms associated with the reactions are
thought to be related to the release of inﬂammatory
cytokines.3 The incidence of infusion reactions was highest
during the ﬁrst infusion (77%) and decreased with each
subsequent infusion.1 Adverse events can include urticaria,
hypotension, angioedema, hypoxia, pulmonary inﬁltrates,
acute respiratory distress syndrome, myocardial infarction,
ventricular ﬁbrillation, or cardiogenic shock. The majority of
severe reactions occur approximately 30–120 min after start-
ing the ﬁrst infusion.1
There are cases described in the literature,4 but our case is
having certain salient and distinguishing features. Our case
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Fig. 3 – (a) Flow established in right coronary artery after use of thrombosuction catheter during primary PCI. (b) Final result of
right coronary artery after successful balloon angioplasty.
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capable institute and the door-to-balloon time was around
40 min. There was baseline thrombocytopenia. Because of
these reasons, we preferred primary angioplasty over phar-
macological thrombolysis. We preloaded the patient with
Aspirin and Prasugrel. Although the patient was having
evidence of underlying coronary artery disease in the coronary
angiogram, he gave no past history of CAD. The current
pathophysiological infract-related lesionwas 100% thrombotic
occlusion of proximal RCA, the LCxwas also showing evidence
of established CAD. After the thrombosuction of RCA lesion,
POBA of RCA showed minimal residual stenosis. Fortunately,
we did not come across any coronary dissection5 with our
POBA results and we deferred the stenting in the view of
thrombocytopenia and need for long-term DAPT.
The proposedmechanismof rituximab inducedmyocardial
infarction could be release of cytokines following death of B
cells that leads to platelet activation, vasoconstriction, and
plaque rupture. The risk could be more in patients with pre-
existing atherosclerosis and vulnerable plaques and advance
stage malignancy. Adequate hydration prior to starting
chemotherapy with rituximab (especially with ﬁrst dose
infusion) might be a preventive strategy as our case revealed
a lot of thrombus burden in the present case. Additionally,
while treating these patients with percutaneous coronary
intervention, complication of coronary dissection should bekept in mind.5 Special devices that are helpful while dealing
with high thrombus burden lesions (e.g. thrombus aspiration
catheter and protection devices) should also be kept ready.
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